| 3.78 0.11 (3%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.15  |
1-year : | 5.91 |
| Resists | First : | 4.41 |
Second : | 5.05 |
| Pivot price | 4.14 |
|||
| Supports | First : | 3.35 | Second : | 2.79 |
| MAs | MA(5) : | 3.79 |
MA(20) : | 4.27 |
| MA(100) : | 3.75  |
MA(250) : | 2.49 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.5 |
D(3) : | 32.7 |
| RSI | RSI(14): 41.6 |
|||
| 52-week | High : | 5.07 | Low : | 1.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MGNX ] has closed above bottom band by 17.8%. Bollinger Bands are 2.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.83 - 3.85 | 3.85 - 3.87 |
| Low: | 3.59 - 3.62 | 3.62 - 3.65 |
| Close: | 3.74 - 3.78 | 3.78 - 3.82 |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Wed, 29 Jul 2026
BlackRock (MGNX holder) discloses 7.1% MacroGenics stake in Schedule 13G filing - Stock Titan
Mon, 27 Jul 2026
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important (MGNX) - Seeking Alpha
Mon, 27 Jul 2026
MacroGenics Inc (MGNX) Institutional Confidence - TradingKey
Sun, 26 Jul 2026
MacroGenics, Inc. Revenue Breakdown – NASDAQ:MGNX - TradingView
Sun, 26 Jul 2026
MGNX|MacroGenics Inc|Price:3.800|Chg%:-0.200 - TradingKey
Fri, 24 Jul 2026
MacroGenics slips on trial data for lead asset (MGNX:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 69 (%) |
| Shares Short | 5,690 (K) |
| Shares Short P.Month | 4,790 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.33 |
| Profit Margin | -44.8 % |
| Operating Margin | -161 % |
| Return on Assets (ttm) | -18 % |
| Return on Equity (ttm) | -140.3 % |
| Qtrly Rev. Growth | 57.5 % |
| Gross Profit (p.s.) | -0.41 |
| Sales Per Share | 2.47 |
| EBITDA (p.s.) | -0.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -70 (M) |
| Levered Free Cash Flow | 10 (M) |
| PE Ratio | -3.41 |
| PEG Ratio | 0 |
| Price to Book value | 11.45 |
| Price to Sales | 1.52 |
| Price to Cash Flow | -3.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|